Anacor Pharmaceuticals, Inc.
(NASDAQ : ANAC)

( )
ANAC PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson 0.31%163.360.7%$1395.05m
PFEPfizer Inc. -0.03%33.790.9%$1240.93m
BMYBristol-Myers Squibb Co. -0.47%61.761.0%$871.78m
MRKMerck & Co., Inc. -0.04%74.550.7%$835.06m
ABBVAbbVie, Inc. -0.09%107.301.9%$808.30m
LLYEli Lilly & Co. -0.32%203.041.1%$779.17m
AZNAstraZeneca Plc 0.59%49.201.2%$523.20m
GSKGlaxoSmithKline Plc -0.38%34.250.2%$269.38m
NVSNovartis AG 0.77%87.440.2%$192.32m
SNYSanofi 1.22%46.360.2%$170.49m
VTRSViatris, Inc. -1.53%14.820.0%$142.10m
VERUVeru, Inc. -3.29%13.810.0%$115.05m
CVACCureVac NV 1.33%94.210.0%$107.67m
VYNEVYNE Therapeutics, Inc. -1.90%7.740.0%$98.29m
NVONovo Nordisk A/S 0.15%72.450.1%$93.17m

Company Profile

Anacor Pharmaceuticals is a biopharmaceutical company that engages in developing small-molecule therapeutics from its boron chemistry platform. It focuses on developing topical applications of its compounds to treat fungal, bacterial, and inflammatory diseases. The company’s primary product candidate, AN2690, is a novel topical antifungal for the treatment of toenail onychomycosis, a fungal infection of the nail and nail bed. It is also developing AN2728, an anti-inflammatory product candidate for the treatment of psoriasis; AN0128, a product candidate that has antibiotic and anti-inflammatory properties; and AN2718, which is in preclinical development for the topical treatment of vaginal candidiasis and tineapedis.